arginine has been researched along with hirudin in 216 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 12 (5.56) | 18.7374 |
1990's | 37 (17.13) | 18.2507 |
2000's | 105 (48.61) | 29.6817 |
2010's | 56 (25.93) | 24.3611 |
2020's | 6 (2.78) | 2.80 |
Authors | Studies |
---|---|
Glusa, E | 1 |
Anderson, PJ; Bock, PE; Nesset, A | 1 |
Catovsky, S; Schini, VB; Scott-Burden, T; Vanhoutte, PM | 1 |
Pearson, JD; Royston, BD; Royston, D | 1 |
Butler, KD; Crook, P; May, GR; Page, CP; Paul, W | 1 |
Loscalzo, J; Scharfstein, J | 1 |
Church, WR; Huang, RS; Rittenhouse, SE; Simons, ER; Sorisky, A | 1 |
De Meester, I; Hendriks, D; Scharpe, S; van Sande, M; Vanhoof, G; Vriend, G | 1 |
Knupp, CL | 2 |
Breddin, HK; Haarmann, W; Krupinski, K; Markwardt, F | 1 |
Kaminski, M; McDonagh, J | 1 |
Fritz, H; Gebhardt, M; Marx, R; Oppitz, I; Oppitz, KH; Werle, E | 1 |
Fink, E; Fritz, H; Gebhardt, M; Hochstrasser, K; Werle, E | 1 |
Brecher, AS; Burkholder, DE; Burkholder, JS; Howe, WF | 1 |
Owen, WG; Wagner, RH | 1 |
Richelson, E; Snider, RM | 1 |
Anderson, ER; Au-Young, YK; Foulks, JG | 1 |
Hoffmann, J; Markwardt, F; Nowak, G | 1 |
Callas, DD; Fareed, J | 2 |
Callas, DD; Fareed, J; Hoppensteadt, D | 1 |
Berry, CN; Girardot, C; Lecoffre, C; Lunven, C | 1 |
Levine, L | 1 |
Banner, DW; Hadváry, P | 1 |
Claeson, G; Ehrhardt, C; Metternich, R; Scully, MF; Stone, SR; Tapparelli, C; Zurini, M | 1 |
Berry, CN; Gauffeny, C; Lecoffre, C; Lunven, C; O'Brien, DP; Roome, NO | 1 |
Coulombe, R; Cygler, M; Féthière, J; Konishi, Y; Tsuda, Y | 1 |
Kleiman, NS | 1 |
Verstraete, M | 2 |
Le Bonniec, BF; Stone, SR | 1 |
Bajzar, L; Côté, HC; MacGillivray, RT; Morser, J; Nesheim, ME; Samis, JA; Stevens, WK | 1 |
Han, JH; Tollefsen, DM; Van Deerlin, VM | 1 |
Callas, D; Fareed, J; Hayes, JM; Iqbal, O; Jeske, W | 1 |
Hermann, JP; Kutryk, MJ; Serruys, PW | 1 |
Prasa, D; Stürzebecher, J; Svendsen, L | 1 |
Deinum, J; Elg, M; Gustafsson, D | 1 |
Deschenes, I; DiMaio, J; Finkle, CD; Leblond, L; St Pierre, A; Winocour, PD | 1 |
Bode, W; Brandstetter, H; Chang, J; Hamaguchi, N; Jin, J; Lollar, P; Stafford, DW; Straight, DL | 1 |
Barrowcliffe, TW; Goodnight, SH; Green, D; Laposata, M; Sosolik, RC; Van Cott, EM | 1 |
De Filippis, V; Di Cera, E; Fontana, A; Quarzago, D; Vindigni, A | 1 |
Dobner, P; Engelmann, B; Hermetter, A; Kögl, C; Schaipp, B; Siess, W; Stoeckelhuber, M | 1 |
Berry, CN; Gandossi, E; Gauffeny, C; Lunven, C; Roome, NO | 1 |
Fukazawa, T; Goto, Y; Hayashi, H; Inoue, Y; Komatsu, Y | 1 |
Agnelli, G; Taliani, MR | 1 |
Jang, IK; Januzzi, JL | 1 |
Armstrong, PW; Choy, JB | 1 |
Cella, G; Girolami, A; Sasahara, AA | 1 |
Greinacher, A; Lubenow, N | 2 |
Baglin, TP | 1 |
Hauptmann, J; Steinmetzer, T; Sturzebecher, J | 1 |
Fleischer, K; Gulba, DC; Lankes, W | 1 |
Alfke, H; Barry, JJ; Bergen, S; Kalinowski, M; Klose, KJ; Wagner, HJ | 1 |
Creekmore, F | 1 |
Dager, WE; White, RH | 1 |
Chew, D; Reginelli, JP | 1 |
Wittkowsky, AK | 1 |
Mendez, MN; Tong, LM | 1 |
Warkentin, TE | 4 |
Smythe, MA; Warkentin, TE | 1 |
Jeske, WP; Walenga, JM | 1 |
Mattson, JC; Smythe, MA; Stephens, JL; Warkentin, TE; Zakalik, D | 1 |
Fenyvesi, T; Harenberg, J; Jörg, I | 1 |
Fenyvesi, T; Harenberg, J; Joerg, I | 1 |
Nguyen, PH; Rice, L; Vann, AR | 1 |
Mukundan, S; Zeigler, ZR | 1 |
Bates, ER; Weitz, JI | 1 |
Califf, RM; O'Shea, S; Reddan, D; Szczech, LA | 1 |
Kaplan, KL | 1 |
Adams, TE; Everse, SJ; Mann, KG | 1 |
SCARZELLA, R; TORRE, M; ZANALDA, A | 1 |
Nielsen, VG | 1 |
Lincoff, AM | 1 |
Jang, IK; Kathiresan, S; Wykrzykowska, JJ | 1 |
Greinacher, A | 1 |
Cleveland, KW | 1 |
Chen, L; Rezaie, AR | 1 |
Heddle, N; Hirsh, J; Kelton, JG | 1 |
Dager, WE; Gosselin, RC; Janatpour, K; King, JH; Larkin, EC; Mahackian, K; Owings, JT | 1 |
Dager, WE; Gosselin, RC; Janatpour, KA; King, JH; Larkin, EC; Owings, JT | 1 |
Call, JT; Deliargyris, EN; Sane, DC | 1 |
Dangas, GD; Nikolsky, E | 1 |
Dager, WH; Gosselin, RC; Janatpur, KA; King, JH; Larkin, EC; Owings, JT | 1 |
Elliott, WG; Gurbuz, AT; Zia, AA | 1 |
Bates, ER; Mukherjee, D | 1 |
Bhatt, DL; Gurm, HS | 1 |
White, CM | 1 |
Fareed, J; Harenberg, J; Kemkes-Matthes, B; Walenga, JM | 1 |
Bartholomew, JR | 1 |
Woodyard, DN | 1 |
Almahameed, A; Bartholomew, JR; Begelman, SM | 1 |
Kam, PC; Kaur, N; Thong, CL | 1 |
Fenyvesi, T; Harenberg, J; Ingrid, J; Job, H; Jörg, I; Lukas, P; Piazolo, L; Tivadar, F | 1 |
Gray, E; Harenberg, J | 1 |
Abrams, CS; Pollak, ES | 1 |
Smith, KM; Taylor, LM | 1 |
Genzen, JR; Miller, JL | 1 |
Charest, AF; Geerts, WH; Grand'Maison, A | 1 |
McIntosh, BA | 1 |
Hyers, TM | 1 |
Chesebro, JH; Grill, DE; Hassinger, NL; McBane, RD; Mruk, JS | 1 |
Hallisey, RK; John, TE | 1 |
Pengo, V | 1 |
Bick, RL; Fareed, J; Messmore, HL; Walenga, JM | 1 |
Koerber, JM; Mattson, JC; Smythe, MA; Stephens, JL | 1 |
Fish, DN; Jung, R; Kiser, TH; MacLaren, R | 1 |
Craven, S; Dewar, L; Greinacher, A; Ofosu, FA; Sheppard, JA; Warkentin, TE | 1 |
Matthai, WH | 1 |
Baker, KM; Flattery, MP | 1 |
Dang, CH; Durkalski, VL; Nappi, JM | 1 |
Gurley, WQ; Kirklin, JK; Lell, WA; Nielsen, VG; Pereira, SJ; Steenwyk, BL | 1 |
Boshkov, LK; Kirby, A; Shen, I; Ungerleider, RM | 1 |
Das, P; Hamdalla, H; Jozic, J; Moliterno, DJ; Mukherjee, D; Steinhubl, SR; Ziada, K | 1 |
Almahameed, A; Napolitano, LM; Nasraway, SA; Warkentin, TE | 1 |
Cooney, MF | 1 |
Hursting, MJ; Lewis, BE | 1 |
Fraser, JF; O'Connor, ED | 1 |
Haas, S; Höhnke, C | 1 |
Blain, RC; Lovejoy, AE; Nakagawa, PA; Nugent, DJ; Yonekawa, KE; Young, G | 1 |
Marymont, JH; Murphy, GS | 1 |
Greinacher, A; Selleng, K; Warkentin, TE | 1 |
Dager, WE; Dougherty, JA; Militello, MA; Nguyen, PH; Smythe, MA | 1 |
Baroletti, S; Fanikos, J; Fiumara, K; Goldhaber, SZ; Luppi, C; Mehta, A; Saniuk, C; Silverman, J | 1 |
Fischer, KG | 1 |
Bong, M; Di Cesare, PE; Patel, VP | 1 |
Ahmed, I; Majeed, A; Powell, R | 1 |
Jolicoeur, EM; Lopes, RD; Ohman, EM; Wang, T | 1 |
Cappellini, MD; Cassinerio, E; Castelli, R; Fabris, F; Graziadei, G; Porro, F | 1 |
Agnelli, G; Filippucci, E; Iorio, A; Vedovati, MC | 1 |
Lepor, NE | 1 |
Cruz-González, I; Jang, IK; Sánchez, PL; Sánchez-Ledesma, M | 1 |
Stief, TW | 1 |
Chiappe, J; Fugate, S | 1 |
Bukys, MA; Kalafatis, M; Kim, PY; Nesheim, ME; Orban, T | 1 |
Prechel, M; Walenga, JM | 1 |
Ansell, JE; Dinwoodey, DL | 1 |
Chevalier, A; Nutescu, EA; Shapiro, NL | 1 |
Rolfes, C; Steinfeldt, T | 1 |
Bauer, KA; Donati, MB; Gould, M; Hirsh, J; Samama, MM; Weitz, JI | 1 |
Colemen, CI; Talati, R; White, CM | 1 |
Greinacher, A; Haneya, A; Hirt, S; Schmid, C; Selleng, K; Selleng, S | 1 |
Billett, HH; Cheng-Lai, A; Curzio, KM; Kheyfets, V; Sinnet, M | 1 |
Kalb, ML; Kozek-Langenecker, SA; Potura, L; Scharbert, G | 1 |
Chong, BH; Isaacs, A | 1 |
Christoffersen, C; Gøtze, JP; Lethagen, S | 1 |
Buerke, M; Friedrich, I; Hamilton, K; Hauroeder, B; Linde, T; Maegdefessel, L; Michel, T; Raaz, U; Schlitt, A; Schubert, S; Steinseifer, U; Werdan, K | 1 |
Chong, BH; Lip, GYH; Shantsila, E | 1 |
Levy, JH; Winkler, AM | 1 |
Ortel, TL | 1 |
Bark, N; Blombäck, M; He, S; Johnsson, H; Wallén, NH | 1 |
Bartholomew, JR; Frame, JN; Rice, L; Whelton, A | 1 |
Ivandic, B; Zorn, M | 1 |
Guan, S; Li, H; Peng, C; Xu, S; Yuan, Z | 1 |
Bandyk, DF; Bartholomew, JR; Boyce, SW; Frame, JN; Rice, L | 1 |
Arnold, H; Deal, EN; Hollands, JM; Martinez, EJ; Micek, ST; Skrupky, LP; Smith, JR | 1 |
Oo, TH | 1 |
Ansell, JE; Lee, CJ | 1 |
Hassell, KL; Kiser, TH; Mann, AM; Trujillo, TC | 1 |
Fries, D | 1 |
Ageno, W; Streif, W | 1 |
Antovic, JP; Armstrong, E; Baghaei, F; Dalsgaard-Nielsen, J; Hillarp, A; Holme, PA; Holmström, M; Johnsson, H; Joutsi-Korhonen, L; Lassila, R; Sandset, PM | 1 |
Young, G | 2 |
Kennedy, K; King, S; Poe, K; Reeves, J; Short, M; Steinke, D | 1 |
Fan, L; Liu, J; Yang, L; Zhang, C; Zhou, J | 1 |
Corbets, LR; Forsyth, LL; Koerber, JM; Mehta, TP; Melendy, SM; Parikh, R; Smythe, MA; Sykes, E | 1 |
Baglin, TP; Garcia, DA; Samama, MM; Weitz, JI | 1 |
Aguilera, TA; Baik, FM; Baird, SM; Crisp, JL; Friedman, B; Jiang, T; Nguyen, QT; Olson, ES; Tsien, RY; Tsimikas, S; Whitney, MA | 1 |
Knovich, MA; Lesser, GJ; Strowd, RE | 1 |
Argueta-Morales, IR; DeCampli, WM; Felix, DE; Munro, HM; Olsen, MC | 1 |
Abel, EE; Kane-Gill, SL; Kellum, JA; Seybert, AL | 1 |
Cruz-González, I; López-Jiménez, R; Perez-Rivera, A; Yan, BP | 1 |
Coppens, M; Eikelboom, JW; Gustafsson, D; Hirsh, J; Weitz, JI | 1 |
Curvers, J; Scharnhorst, V; Stroobants, AK; van de Kerkhof, D; van den Dool, EJ | 1 |
Cooper, T; Kokko, H; Mazur, J; Taber, D; Uber, WE; White, CL | 1 |
Fritsma, GA | 1 |
Pötzsch, B | 1 |
Bereczky, Z; Boda, Z; Kappelmayer, J; Kerenyi, A; Olah, Z; Szarvas, M | 1 |
Bleker, SM; Büller, HR; Coppens, M; van Es, N | 1 |
Boyle, ME; Fisher, S; Ishimoto, J; Kiser, TH; Lind, SE; Trujillo, TC | 1 |
Bartholomew, JR; Casanegra, AI; Dhariwal, M; Gomes, MP; Gornik, HL; Joseph, L; Militello, MA; Raju, MG; Smith, MA | 1 |
Moffett, BS; Teruya, J | 1 |
Kadauke, S; Khor, B; Van Cott, EM | 1 |
Bahlmann, A; Beiderlinden, M; Brezina, T; Geib, J; Golla, E; Greinacher, A; Kienbaum, P; Kindgen-Milles, D; Pannen, B; Schaefer, MS; Treschan, TA; Werner, P | 1 |
Lin, JK; Tong, LM; Vo, QA | 1 |
Adams, CD; Anne Hirning, B; Blum, RM; Fanikos, J; Gilmore, JF; Matta, L | 1 |
Bain, J; Meyer, A | 1 |
Albers, EL; Dickey, R; Falconer, A; Jefferis Kirk, C; Latham, GJ; McMullan, DM | 1 |
Golovin, A; Kopylov, A; Pavlova, G; Ustinov, N; Zavyalova, E | 1 |
Adams, DH; Evans, AS; Fischer, GW; Heller, J; Salter, BS; Trinh, MA; Weiner, MM | 1 |
Kopylov, AM; Ustinov, NB; Zav'yalova, EG | 1 |
Harada, MY; Hoang, DM; Ley, EJ; Margulies, DR; Mason, R; Murry, JS; Nuño, M; Sun, BJ; Volod, O; Zaw, AA | 1 |
Lei, BZ; Sendowski, M; Shatzel, JJ | 1 |
Dager, WE; Roberts, AJ; Van Cott, EM | 1 |
Kolde, HJ; Seidel, H | 1 |
Male, C; van Ommen, CH; Young, G | 1 |
Lan, X; Li, S; Sun, Z; Tang, Z; Xi, Y; Zhao, H | 1 |
Banik, N; Beyer-Westendorf, J; Brachmann, J; Dohmen, PM; Eberle, S; Hankowitz, J; Klamroth, R; Kropff, S; Lindhoff-Last, E; Madlener, K; Müller, MM; Pötzsch, B; Schellong, S; Schindewolf, M; Steindl, J | 1 |
Faraoni, D; Koster, A; Levy, JH | 1 |
Ananth, CV; D'Alton, ME; Eisenberger, AB; Friedman, AM; Sagaram, D; Siddiq, Z; Wright, JD | 1 |
Bahlmann, A; Beiderlinden, M; Brezina, T; Görlinger, K; Kemper, J; Kienbaum, P; Schäfer, M; Seidel, H; Treschan, TA; Werner, P | 1 |
Chang, HT; Chu, HW; Huang, CC; Lai, PX; Mao, JY; Unnikrishnan, B; Wu, CW | 1 |
Arepally, GM; Chong, BH; Cines, DB; Cuker, A; Greinacher, A; Gruel, Y; Linkins, LA; Morgan, RL; Mustafa, RA; Rodner, SB; Santesso, N; Selleng, S; Warkentin, TE; Wex, A | 1 |
Beyer, JT; Fisher, S; Kiser, TH; Lind, SE; Trujillo, TC; Wempe, MF | 1 |
Briski, MJ; Duewell, BE; Feih, JT; Rinka, JRG; Tawil, JN | 1 |
Allender, JE; Coons, JC; Cox, JF; DiDomenico, RJ; Jennings, DL; Johnson, D; Oliphant, CS; Reed, BN | 1 |
Berlioz, B; Guru, PK; Kaseer, HS; Sanghavi, DK | 1 |
Boyle, G; Buchholz, H; Cantor, RS; Conway, J; Fynn-Thompson, F; Griffiths, E; Hawkins, B; Lorts, A; Lytrivi, ID; Machado, D; May, L; Niebler, RA; Rossano, J; Sutcliffe, DL; VanderPluym, CJ | 1 |
Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y | 1 |
González-Rodríguez, M; Lázaro-García, A; Llamas-Sillero, P; Martínez-Alfonzo, I; Tomás-Mallebrera, M; Velasco-Rodríguez, D; Vidal-Laso, R | 1 |
86 review(s) available for arginine and hirudin
Article | Year |
---|---|
Molecular approaches to antithrombotic therapy.
Topics: Amino Acid Chloromethyl Ketones; Antithrombins; Arginine; Heparin; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Protease Inhibitors; Sulfonamides; Thrombin; Warfarin | 1992 |
Proteases and their inhibitors: today and tomorrow.
Topics: Amino Acid Sequence; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Endopeptidases; Heparin; Hirudins; HIV Protease; HIV Protease Inhibitors; Humans; Molecular Sequence Data; Peptidyl-Dipeptidase A; Pipecolic Acids; Protease Inhibitors; Recombinant Proteins; Renin; Sulfonamides; Thrombin | 1991 |
Inhibitor binding to thrombin: x-ray crystallographic studies.
Topics: Amino Acid Sequence; Antithrombins; Arginine; Binding Sites; Crystallography, X-Ray; Dipeptides; Hirudins; Molecular Sequence Data; Molecular Structure; Pipecolic Acids; Piperidines; Sulfonamides; Thrombin | 1993 |
Clinical trials of conjunctive anticoagulant strategies in thrombolysis.
Topics: Anticoagulants; Antithrombins; Arginine; Blood Platelets; Clinical Trials as Topic; Epoprostenol; Heparin; Hirudin Therapy; Hirudins; Humans; Myocardial Infarction; Oligopeptides; Peptide Fragments; Pipecolic Acids; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Sulfonamides; Thrombin; Thrombolytic Therapy | 1996 |
Modulating platelet function with selective thrombin inhibitors.
Topics: Administration, Oral; Adult; Animals; Antithrombins; Arginine; Blood Platelets; Boron Compounds; Clinical Trials as Topic; Dogs; Drug Evaluation, Preclinical; Glycine; Hirudin Therapy; Hirudins; Humans; Naphthalenes; Oligopeptides; Peptide Fragments; Pipecolic Acids; Piperidines; Recombinant Proteins; Sulfonamides; Thrombin | 1996 |
Direct thrombin inhibitors: appraisal of the antithrombotic/hemorrhagic balance.
Topics: Antithrombins; Arginine; Clinical Trials, Phase III as Topic; Fibrinolytic Agents; Hemorrhage; Hirudin Therapy; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides | 1997 |
Clinical trials of direct thrombin inhibitors during invasive procedures.
Topics: Antithrombins; Arginine; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Endothelium, Vascular; Fibrinolytic Agents; Hirudin Therapy; Hirudins; Humans; Pipecolic Acids; Sulfonamides | 1997 |
College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban.
Topics: Anticoagulants; Arginine; Chondroitin Sulfates; Dermatan Sulfate; Drug Combinations; Drug Monitoring; Heparin; Heparin, Low-Molecular-Weight; Heparitin Sulfate; Hirudin Therapy; Hirudins; Humans; Pathology, Clinical; Pipecolic Acids; Sulfonamides; Thromboembolism | 1998 |
[New antithrombotic drugs].
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Arginine; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Dermatan Sulfate; Eptifibatide; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Hirudin Therapy; Hirudins; Humans; Immunoglobulin Fab Fragments; Multicenter Studies as Topic; Peptide Fragments; Peptides; Pilot Projects; Pipecolic Acids; Platelet Aggregation Inhibitors; Recombinant Proteins; Sulfonamides | 1999 |
Heparin induced thrombocytopenia: diagnosis and contemporary antithrombin management.
Topics: Ancrod; Arginine; Chondroitin Sulfates; Dermatan Sulfate; Drug Combinations; Fibrinolytic Agents; Forecasting; Gangrene; Hemorrhage; Heparin; Heparitin Sulfate; Hirudin Therapy; Hirudins; Humans; Pipecolic Acids; Platelet Aggregation; Protein C; Recombinant Proteins; Sulfonamides; Thrombin; Thrombocytopenia; Warfarin | 1999 |
Anticoagulant therapy in unstable angina.
Topics: Angina, Unstable; Anticoagulants; Antithrombins; Arginine; Clinical Trials as Topic; Coronary Thrombosis; Disease Progression; Heparin; Heparin, Low-Molecular-Weight; Hirudin Therapy; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Warfarin | 1999 |
Management of patients with heparin-induced thrombocytopenia: focus on recombinant hirudin.
Topics: Anticoagulants; Antithrombins; Arginine; Chondroitin Sulfates; Clinical Trials as Topic; Critical Pathways; Dermatan Sulfate; Drug Combinations; Fibrinolytic Agents; Heparin; Heparinoids; Heparitin Sulfate; Hirudin Therapy; Hirudins; Humans; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombocytopenia | 2000 |
Heparin induced thrombocytopenia thrombosis (HIT/T) syndrome: diagnosis and treatment.
Topics: Anticoagulants; Arginine; Heparin; Hirudin Therapy; Hirudins; Humans; Pipecolic Acids; Platelet Count; Recombinant Proteins; Sulfonamides; Thrombocytopenia; Thrombosis | 2001 |
Advances in the development of thrombin inhibitors.
Topics: Arginine; Azetidines; Benzylamines; Clinical Trials as Topic; Glycine; Hirudin Therapy; Hirudins; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombin | 2001 |
[Direct thrombin antagonists].
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Antithrombins; Arginine; Azetidines; Benzylamines; Fibrinolytic Agents; Glycine; Hirudin Therapy; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Pipecolic Acids; Platelet Aggregation Inhibitors; Rabbits; Recombinant Proteins; Sulfonamides; Syndrome; Thrombin; Thromboembolism; Thrombosis; Time Factors | 2001 |
Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data.
Topics: Angina, Unstable; Antithrombins; Arginine; Glycine; Heparin; Hirudin Therapy; Hirudins; Humans; Myocardial Infarction; Oligopeptides; Peptide Fragments; Pipecolic Acids; Piperidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Sulfonamides; Survival Rate; Thrombin | 2002 |
Treatment of heparin-induced thrombocytopenia.
Topics: Animals; Anticoagulants; Arginine; Chondroitin Sulfates; Clinical Trials as Topic; Coronary Disease; Dermatan Sulfate; Drug Combinations; Female; Heparin; Heparitin Sulfate; Hirudin Therapy; Hirudins; Humans; Pipecolic Acids; Pregnancy; Rabbits; Recombinant Proteins; Sulfonamides; Thrombocytopenia | 2002 |
Direct thrombin inhibitors for percutaneous coronary intervention in the current era of platelet glycoprotein IIb/IIIa inhibition.
Topics: Angioplasty, Balloon, Coronary; Arginine; Coronary Thrombosis; Drug Therapy, Combination; Fibrinolytic Agents; Hirudin Therapy; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Sulfonamides | 2002 |
The role of thrombin inhibition during percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Arginine; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Fibrinolytic Agents; Fondaparinux; Heparin; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Polysaccharides; Recombinant Proteins; Sulfonamides; Thrombin | 2002 |
Therapeutic considerations in the management of patients with heparin-induced thrombocytopenia.
Topics: Anticoagulants; Arginine; Azetidines; Benzylamines; Fondaparinux; Heparin; Hirudin Therapy; Hirudins; Humans; Pipecolic Acids; Polysaccharides; Prodrugs; Recombinant Proteins; Sulfonamides; Thrombin; Thrombocytopenia | 2002 |
Current agents for the treatment of patients with heparin-induced thrombocytopenia.
Topics: Anticoagulants; Antithrombins; Arginine; Autoimmune Diseases; Chondroitin Sulfates; Dermatan Sulfate; Drug Combinations; Heparin; Heparitin Sulfate; Hirudin Therapy; Hirudins; Humans; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombocytopenia; Warfarin | 2002 |
Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia.
Topics: Animals; Anticoagulants; Antithrombins; Arginine; Chondroitin Sulfates; Dermatan Sulfate; Drug Combinations; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Heparitin Sulfate; Hirudins; Humans; Pipecolic Acids; Platelet Aggregation Inhibitors; Recombinant Proteins; Sulfonamides; Thrombocytopenia | 2002 |
Hirudin in heparin-induced thrombocytopenia.
Topics: Anticoagulants; Antithrombins; Arginine; Blood Coagulation; Chondroitin Sulfates; Clinical Trials as Topic; Dermatan Sulfate; Drug Combinations; Fibrinolytic Agents; Heparin; Heparitin Sulfate; Hirudin Therapy; Hirudins; Humans; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombocytopenia; Thrombosis; Time Factors | 2002 |
Direct thrombin inhibitors in cardiac disease.
Topics: Arginine; Coronary Disease; Fibrinolytic Agents; Hirudin Therapy; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Randomized Controlled Trials as Topic; Recombinant Proteins; Sulfonamides; Thrombin | 2003 |
Direct thrombin inhibitors.
Topics: Antithrombins; Arginine; Coronary Disease; Half-Life; Hirudins; Humans; Metabolic Clearance Rate; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombin; Venous Thrombosis | 2003 |
Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban.
Topics: Anticoagulants; Antithrombins; Arginine; Female; Heparin; Hirudins; Humans; Middle Aged; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombocytopenia | 2003 |
Direct thrombin inhibitors for non-ST-segment elevation acute coronary syndromes: what, when, and where?
Topics: Angioplasty, Balloon, Coronary; Arginine; Clinical Trials as Topic; Coronary Disease; Fibrinolytic Agents; Heparin; Hirudin Therapy; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Syndrome; Thrombin; Thrombolytic Therapy | 2003 |
Argatroban, a new treatment option for heparin-induced thrombocytopenia.
Topics: Anticoagulants; Antithrombins; Arginine; Blood Coagulation; Blood Coagulation Tests; Chondroitin Sulfates; Critical Care; Dermatan Sulfate; Drug Combinations; Drug Costs; Drug Monitoring; Heparin; Heparitin Sulfate; Hirudins; Humans; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombocytopenia | 2003 |
Treatment of heparin-induced thrombocytopenia: a critical review.
Topics: Anticoagulants; Arginine; Heparin; Hirudins; Humans; Pipecolic Acids; Recombinant Proteins; Risk Assessment; Sulfonamides; Thrombocytopenia; Thrombosis | 2004 |
Direct thrombin inhibitors in the treatment of immune-mediated heparin-induced thrombocytopenia.
Topics: Anticoagulants; Arginine; Binding Sites; Heparin; Hirudins; Humans; Models, Biological; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Syndrome; Thrombin; Thrombocytopenia; Treatment Outcome | 2004 |
Percutaneous interventions in patients with immune-mediated heparin-induced thrombocytopenia.
Topics: Anticoagulants; Arginine; Blood Platelets; Heparin; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Skin; Sulfonamides; Thrombin; Thrombocytopenia; Time Factors | 2004 |
Heparin-induced thrombocytopenia: diagnosis and management.
Topics: Anticoagulants; Aortic Valve Insufficiency; Arginine; Autoantibodies; Autoimmune Diseases; Female; Fingers; Heart Valve Prosthesis Implantation; Heparin; Hirudins; Humans; Ischemia; Middle Aged; Necrosis; Pipecolic Acids; Platelet Activation; Platelet Factor 4; Postoperative Complications; Raynaud Disease; Recombinant Proteins; Sulfonamides; Thrombocytopenia; Thrombosis; Toes; Warfarin | 2004 |
Heparin-induced thrombocytopenia in the cardiovascular patient: diagnostic and treatment guidelines.
Topics: Ancrod; Antibodies; Anticoagulants; Arginine; Cardiovascular Diseases; Chondroitin Sulfates; Dermatan Sulfate; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Heparitin Sulfate; Hirudin Therapy; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Practice Guidelines as Topic; Purpura, Thrombocytopenic, Idiopathic; Recombinant Proteins; Sulfonamides; Thrombin | 2005 |
Current role of antithrombotic agents in the treatment of acute coronary syndromes.
Topics: Aged; Anticoagulants; Arginine; Blood Platelets; Clinical Trials as Topic; Enoxaparin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Hirudins; Humans; Middle Aged; Models, Biological; Myocardial Infarction; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Risk; Sulfonamides; Thrombin | 2004 |
Thrombin, an ideal target for pharmacological inhibition: a review of direct thrombin inhibitors.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Anticoagulants; Arginine; Atrial Fibrillation; Azetidines; Benzylamines; Clinical Trials as Topic; Coronary Disease; Heparin; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Syndrome; Thrombin; Thromboembolism; Thrombosis; Venous Thrombosis | 2005 |
Thrombin-directed inhibitors: pharmacology and clinical use.
Topics: Anticoagulants; Arginine; Azetidines; Benzylamines; Blood Coagulation; Fondaparinux; Heparin; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Polysaccharides; Recombinant Proteins; Sulfonamides; Thrombin; Thrombosis; Warfarin | 2005 |
Transition to an oral anticoagulant in patients with heparin-induced thrombocytopenia.
Topics: Administration, Oral; Anticoagulants; Arginine; Blood Coagulation; Blood Coagulation Factors; Chondroitin Sulfates; Dermatan Sulfate; Drug Combinations; Gangrene; Heparin; Heparitin Sulfate; Hirudins; Humans; Ischemia; Leg; Necrosis; Pipecolic Acids; Recombinant Proteins; Skin; Sulfonamides; Thrombocytopenia; Thrombosis; Warfarin | 2005 |
An anesthesia provider's perspective of heparin-induced thrombocytopenia.
Topics: Anesthesia, General; Anticoagulants; Arginine; Drug Monitoring; Enzyme-Linked Immunosorbent Assay; Heparin; Hirudins; Humans; Intraoperative Care; Nurse Anesthetists; Pipecolic Acids; Platelet Count; Recombinant Proteins; Risk Factors; Sensitivity and Specificity; Severity of Illness Index; Sulfonamides; Thrombocytopenia; Thrombosis; Time Factors | 2005 |
Heparin-induced thrombocytopenia: principles for early recognition and management.
Topics: Anticoagulants; Arginine; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; Pipecolic Acids; Platelet Count; Practice Guidelines as Topic; Recombinant Proteins; Risk Assessment; Sulfonamides; Thrombocytopenia; Time Factors | 2005 |
Direct thrombin inhibitors: pharmacology and clinical relevance.
Topics: Anticoagulants; Antithrombins; Arginine; Azetidines; Benzylamines; Fibrinolytic Agents; Hirudins; Humans; Pipecolic Acids; Sulfonamides; Thrombosis | 2005 |
Clinical presentation and laboratory diagnosis of heparin-induced thrombocytopenia.
Topics: Anticoagulants; Arginine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heparin, Low-Molecular-Weight; Hirudins; Humans; Male; Pipecolic Acids; Recombinant Proteins; Risk Assessment; Severity of Illness Index; Sulfonamides; Thrombocytopenia; Thrombosis; Treatment Outcome | 2005 |
Anticoagulant use in patients with chronic renal impairment.
Topics: Anticoagulants; Arginine; Azetidines; Benzylamines; Fondaparinux; Heparin; Hirudins; Humans; Kidney Failure, Chronic; Peptide Fragments; Pipecolic Acids; Polysaccharides; Recombinant Proteins; Sulfonamides; Warfarin | 2005 |
Developing an algorithm for treating heparin-induced thrombocytopenia.
Topics: Algorithms; Anticoagulants; Antigen-Antibody Complex; Arginine; Clinical Trials as Topic; Diagnosis, Differential; Disease Management; Follow-Up Studies; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; Immunoglobulin G; Pipecolic Acids; Platelet Activation; Platelet Count; Platelet Factor 4; Prognosis; Purpura, Thrombocytopenic, Idiopathic; Recombinant Proteins; Sulfonamides; Thrombocytopenia; Thrombophilia; Time Factors | 2004 |
Heparin and other rapidly acting anticoagulants.
Topics: Anticoagulants; Arginine; Azetidines; Benzylamines; Embolism; Enzyme Inhibitors; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Polysaccharides; Recombinant Proteins; Sulfonamides; Thrombin; Thrombocytopenia; Venous Thrombosis | 2005 |
New trends in anticoagulant treatments.
Topics: Anticoagulants; Arginine; Azetidines; Benzylamines; Drug Design; Fibrinolytic Agents; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Platelet Aggregation Inhibitors; Prodrugs; Recombinant Proteins; Sulfonamides; Thrombosis | 2005 |
Treatment of heparin-induced thrombocytopenia in cardiovascular patients.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Arginine; Cardiovascular Diseases; Chondroitin Sulfates; Dermatan Sulfate; Drug Administration Schedule; Factor Xa Inhibitors; Fondaparinux; Heparin; Heparitin Sulfate; Hirudins; Humans; Pipecolic Acids; Polysaccharides; Postoperative Complications; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Recombinant Proteins; Sulfonamides; Thrombin; Thrombocytopenia | 2006 |
Recognition and management of heparin-induced thrombocytopenia in pediatric cardiopulmonary bypass patients.
Topics: Adolescent; Anticoagulants; Arginine; Autoantibodies; Cardiopulmonary Bypass; Child; Child, Preschool; Clinical Trials as Topic; Fatal Outcome; Female; Heart Defects, Congenital; Heparin; Hirudins; Hospitals, University; Humans; Hypoplastic Left Heart Syndrome; Infant; Infant, Newborn; Male; Multicenter Studies as Topic; Pipecolic Acids; Platelet Factor 4; Postoperative Complications; Postoperative Hemorrhage; Recombinant Proteins; Retrospective Studies; Sulfonamides; Thrombocytopenia; Thromboembolism; Treatment Outcome | 2006 |
Heparin-induced thrombocytopenia and cardiovascular diseases.
Topics: Anticoagulants; Arginine; Cardiac Surgical Procedures; Cardiovascular Diseases; Chondroitin Sulfates; Dermatan Sulfate; Diagnosis, Differential; Fondaparinux; Heparin; Heparitin Sulfate; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Platelet Aggregation Inhibitors; Platelet Factor 4; Polysaccharides; Recombinant Proteins; Sensitivity and Specificity; Sulfonamides; Thrombocytopenia; Thrombosis | 2006 |
Heparin-induced thrombocytopenia in the critical care setting: diagnosis and management.
Topics: Anticoagulants; Arginine; Chondroitin Sulfates; Clinical Trials as Topic; Critical Care; Dermatan Sulfate; Heparin; Heparinoids; Heparitin Sulfate; Hirudins; Humans; Pipecolic Acids; Platelet Count; Recombinant Proteins; Risk Factors; Sulfonamides; Thrombin; Thrombocytopenia | 2006 |
Heparin-induced thrombocytopenia: advances in diagnosis and treatment.
Topics: Administration, Oral; Anticoagulants; Arginine; Critical Care; Drug Monitoring; Enzyme-Linked Immunosorbent Assay; Heparin; Hirudins; Humans; International Normalized Ratio; Nurse's Role; Nursing Assessment; Partial Thromboplastin Time; Patient Selection; Pipecolic Acids; Platelet Count; Practice Guidelines as Topic; Recombinant Proteins; Risk Factors; Sulfonamides; Syndrome; Thrombocytopenia; Time Factors | 2006 |
Direct thrombin inhibition during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
Topics: Angioplasty, Balloon, Coronary; Antithrombins; Arginine; Drug Interactions; Economics, Pharmaceutical; Fibrinolytic Agents; Hemorrhage; Heparin; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Platelet Aggregation Inhibitors; Recombinant Proteins; Sulfonamides; Thrombocytopenia; Thrombosis | 2007 |
Heparin-induced thrombocytopenia without thrombosis: an evidence-based review of current literature.
Topics: Anticoagulants; Arginine; Chondroitin Sulfates; Dermatan Sulfate; Evidence-Based Medicine; Heparin; Heparitin Sulfate; Hirudins; Humans; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombocytopenia | 2006 |
Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery.
Topics: Ancrod; Anticoagulants; Arginine; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Chondroitin Sulfates; Dermatan Sulfate; Heparin; Heparin, Low-Molecular-Weight; Heparitin Sulfate; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Platelet Aggregation Inhibitors; Recombinant Proteins; Sulfonamides; Thrombocytopenia | 2007 |
Heparin-induced thrombocytopenia in intensive care patients.
Topics: Anticoagulants; Arginine; Chondroitin Sulfates; Dermatan Sulfate; Extracorporeal Circulation; Heparin; Heparitin Sulfate; Hirudins; Humans; Intensive Care Units; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombin; Thrombocytopenia; Thrombosis | 2007 |
Heparin-induced thrombocytopenia: treatment options and special considerations.
Topics: Anticoagulants; Antithrombins; Arginine; Heparin; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombocytopenia; Thrombosis | 2007 |
Essentials of anticoagulation in hemodialysis.
Topics: Anticoagulants; Arginine; Blood Coagulation; Chondroitin Sulfates; Dermatan Sulfate; Equipment Failure; Hemorrhage; Heparin; Heparitin Sulfate; Hirudins; Humans; Pipecolic Acids; Recombinant Proteins; Renal Dialysis; Renal Insufficiency, Chronic; Sulfonamides | 2007 |
Heparin-induced thrombocytopenia and thrombosis.
Topics: Anticoagulants; Arginine; Chondroitin Sulfates; Dermatan Sulfate; Heparin; Heparitin Sulfate; Hirudins; Humans; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombocytopenia; Thrombosis | 2007 |
Heparin induced thrombocytopenia: diagnosis and management update.
Topics: Anticoagulants; Arginine; Cardiovascular Surgical Procedures; Chondroitin Sulfates; Dermatan Sulfate; Fibrinolytic Agents; Hemorrhage; Heparin; Heparitin Sulfate; Hirudins; Humans; Pipecolic Acids; Recombinant Proteins; Renal Dialysis; Sulfonamides; Thrombocytopenia; Warfarin | 2007 |
Percutaneous coronary interventions in patients with heparin-induced thrombocytopenia.
Topics: Algorithms; Angioplasty, Balloon, Coronary; Anticoagulants; Arginine; Chondroitin Sulfates; Comorbidity; Dermatan Sulfate; Drug Therapy, Combination; Fibrinolytic Agents; Fondaparinux; Heparin; Heparinoids; Heparitin Sulfate; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Pipecolic Acids; Polysaccharides; Recombinant Proteins; Sulfonamides; Syndrome; Thrombocytopenia; Vitamin K | 2007 |
Heparin induced thrombocytopenia: pathogenetic, clinical, diagnostic and therapeutic aspects.
Topics: Animals; Anticoagulants; Arginine; Chondroitin Sulfates; Dermatan Sulfate; Heparin; Heparitin Sulfate; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Postoperative Complications; Recombinant Proteins; Sulfonamides; Thrombocytopenia | 2007 |
Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors.
Topics: Acute Disease; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Arginine; Fondaparinux; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; Models, Molecular; Molecular Structure; Myocardial Ischemia; Peptide Fragments; Pipecolic Acids; Platelet Activation; Polysaccharides; Recombinant Proteins; Sulfonamides; Syndrome; Thrombin; Thrombosis | 2007 |
[Heparin-induced thrombocytopenia].
Topics: Anticoagulants; Arginine; Chondroitin Sulfates; Dermatan Sulfate; Fibrinolytic Agents; Fondaparinux; Heparin; Heparitin Sulfate; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Polysaccharides; Recombinant Proteins; Sulfonamides; Thrombocytopenia | 2007 |
The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update.
Topics: Anticoagulants; Arginine; Chondroitin Sulfates; Dermatan Sulfate; Enzyme-Linked Immunosorbent Assay; Factor Xa Inhibitors; Heparin; Heparitin Sulfate; Hirudins; Peptide Fragments; Pipecolic Acids; Platelet Factor 4; Platelet Function Tests; Recombinant Proteins; Sulfonamides; Thrombin; Thrombocytopenia | 2008 |
Heparins, low-molecular-weight heparins, and pentasaccharides: use in the older patient.
Topics: Aged; Anticoagulants; Arginine; Enoxaparin; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; Pipecolic Acids; Polysaccharides; Recombinant Proteins; Sulfonamides | 2008 |
New anticoagulant agents: direct thrombin inhibitors.
Topics: Anticoagulants; Arginine; Atrial Fibrillation; Benzimidazoles; Dabigatran; Fibrinolytic Agents; Half-Life; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Pyridines; Recombinant Proteins; Stroke; Sulfonamides; Thrombin | 2008 |
Heparin-induced thrombocytopenia: a review of current pharmacologic treatment.
Topics: Anticoagulants; Antithrombin III; Arginine; Fondaparinux; Heparin; Hirudins; Humans; Pipecolic Acids; Polysaccharides; Recombinant Proteins; Sulfonamides; Thrombin; Thrombocytopenia | 2008 |
Heparin-induced thrombocytopenia: what clinicians need to know.
Topics: Anticoagulants; Arginine; Autoantibodies; Chondroitin Sulfates; Dermatan Sulfate; Drug Monitoring; Fondaparinux; Heparin; Heparitin Sulfate; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Platelet Count; Platelet Factor 4; Polysaccharides; Recombinant Proteins; Sulfonamides; Thrombocytopenia; Thrombosis; Warfarin | 2009 |
Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management.
Topics: Anticoagulants; Arginine; Chondroitin Sulfates; Dermatan Sulfate; Female; Heparin; Heparitin Sulfate; Hirudins; Humans; Male; Monitoring, Physiologic; Peptide Fragments; Pipecolic Acids; Platelet Aggregation Inhibitors; Platelet Count; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Risk Factors; Safety Management; Severity of Illness Index; Sulfonamides; Survival Rate; Thrombocytopenia; Thrombosis; Time Factors | 2009 |
Heparin-induced thrombocytopenia and cardiac surgery.
Topics: Anticoagulants; Arginine; Cardiovascular Surgical Procedures; Heparin; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Platelet Activation; Platelet Count; Platelet Factor 4; Recombinant Proteins; Sulfonamides; Thrombin; Thrombocytopenia | 2010 |
Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation.
Topics: Anticoagulants; Arginine; Autoantibodies; Contraindications; Disseminated Intravascular Coagulation; Fondaparinux; Heparin; Hirudins; Humans; Pipecolic Acids; Platelet Count; Platelet Factor 4; Polysaccharides; Recombinant Proteins; Sulfonamides; Thrombocytopenia; Thrombophilia; Time Factors; Venous Thromboembolism; Vitamin K; Warfarin | 2009 |
Direct thrombin inhibitors.
Topics: Anticoagulants; Antithrombins; Arginine; Benzimidazoles; Dabigatran; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Pyridines; Recombinant Proteins; Sulfonamides; Thrombin; Venous Thromboembolism | 2011 |
Thrombosis prophylaxis in critically ill patients.
Topics: Anticoagulants; Arginine; Biological Availability; Chromosome Breakage; Chromosome Disorders; Critical Care; Dose-Response Relationship, Drug; Drug Resistance; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; Infusions, Intravenous; Injections, Subcutaneous; Pipecolic Acids; Recombinant Proteins; Risk Factors; Sepsis; Severity of Illness Index; Shock, Septic; Sulfonamides; Thrombin; Thrombocytopenia; Venous Thrombosis | 2011 |
Direct thrombin and factor Xa inhibitors in children: a quest for new anticoagulants for children.
Topics: Adolescent; Anticoagulants; Arginine; Benzimidazoles; beta-Alanine; Child; Child, Preschool; Dabigatran; Drug Approval; Factor Xa Inhibitors; Fondaparinux; Hirudins; Humans; Infant; Infant, Newborn; Morpholines; Peptide Fragments; Pipecolic Acids; Polysaccharides; Recombinant Proteins; Risk Factors; Rivaroxaban; Sulfonamides; Thiophenes; Thrombin; Venous Thromboembolism | 2011 |
Old and new antithrombotic drugs in neonates and infants.
Topics: Anticoagulants; Arginine; Fondaparinux; Heparin, Low-Molecular-Weight; Hirudins; Humans; Infant; Infant, Newborn; Peptide Fragments; Pipecolic Acids; Polysaccharides; Recombinant Proteins; Sulfonamides; Venous Thromboembolism; Warfarin | 2011 |
Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Antithrombins; Arginine; Chondroitin Sulfates; Dermatan Sulfate; Dose-Response Relationship, Drug; Evidence-Based Medicine; Fibrinolytic Agents; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Heparitin Sulfate; Hirudins; Humans; Infusions, Intravenous; Peptide Fragments; Pipecolic Acids; Polysaccharides; Practice Guidelines as Topic; Recombinant Proteins; Societies, Medical; Sulfonamides; Thrombin; Thrombosis; United States | 2012 |
Pharmacokinetic evaluation of argatroban for the treatment of acute coronary syndrome.
Topics: Acute Coronary Syndrome; Animals; Antithrombins; Arginine; Disease Models, Animal; Drug Evaluation; Heparin; Hirudins; Humans; Peptide Fragments; Percutaneous Coronary Intervention; Pipecolic Acids; Randomized Controlled Trials as Topic; Recombinant Proteins; Sulfonamides; Thrombocytopenia; Thrombosis | 2012 |
Translational success stories: development of direct thrombin inhibitors.
Topics: Anticoagulants; Antithrombins; Arginine; Hirudin Therapy; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombosis; Translational Research, Biomedical | 2012 |
[Anticoagulation].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Arginine; Arrhythmias, Cardiac; Blood Coagulation Tests; Factor Xa Inhibitors; Hemorrhage; Heparin; Heparinoids; Hirudins; Humans; Infusions, Intravenous; Orthopedic Procedures; Peptide Fragments; Pipecolic Acids; Postoperative Complications; Pulmonary Embolism; Recombinant Proteins; Risk Factors; Secondary Prevention; Sulfonamides; Thromboembolism; Treatment Outcome; Venous Thrombosis; Vitamin K | 2013 |
New developments in parenteral anticoagulation for arterial and venous thromboembolism.
Topics: Acute Coronary Syndrome; Antithrombins; Arginine; Fondaparinux; Hirudin Therapy; Hirudins; Humans; Infusions, Parenteral; Peptide Fragments; Percutaneous Coronary Intervention; Pipecolic Acids; Polysaccharides; Randomized Controlled Trials as Topic; Recombinant Proteins; Sulfonamides; Thrombin; Venous Thromboembolism | 2013 |
Anticoagulants in children and adolescents.
Topics: Adolescent; Anticoagulants; Arginine; Child; Clinical Trials as Topic; Fondaparinux; Hematology; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Polysaccharides; Recombinant Proteins; Sulfonamides; Thrombin; Thrombosis; Treatment Outcome; Warfarin | 2015 |
G-Quadruplex Aptamers to Human Thrombin Versus Other Direct Thrombin Inhibitors: The Focus on Mechanism of Action and Drug Efficiency as Anticoagulants.
Topics: Anticoagulants; Antithrombins; Aptamers, Nucleotide; Arginine; Blood Coagulation; G-Quadruplexes; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombin | 2016 |
Heparin-Induced Thrombocytopenia: A Comprehensive Clinical Review.
Topics: Anticoagulants; Antithrombins; Arginine; Cardiopulmonary Bypass; Fondaparinux; Heparin; Hirudins; Humans; Incidence; Peptide Fragments; Percutaneous Coronary Intervention; Pipecolic Acids; Plasmapheresis; Platelet Function Tests; Platelet Transfusion; Polysaccharides; Recombinant Proteins; Risk Factors; Sulfonamides; Thrombocytopenia | 2016 |
Laboratory Monitoring of Parenteral Direct Thrombin Inhibitors.
Topics: Antithrombins; Arginine; Drug Monitoring; Hirudins; Humans; Infusions, Parenteral; Partial Thromboplastin Time; Peptide Fragments; Pipecolic Acids; Point-of-Care Systems; Recombinant Proteins; Sulfonamides; Thrombin; Thrombin Time | 2017 |
Comparisons of argatroban to lepirudin and bivalirudin in the treatment of heparin-induced thrombocytopenia: a systematic review and meta-analysis.
Topics: Arginine; Female; Heparin; Hirudins; Humans; Male; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombocytopenia | 2017 |
Argatroban and Bivalirudin for Perioperative Anticoagulation in Cardiac Surgery.
Topics: Antithrombins; Arginine; Cardiac Surgical Procedures; Hirudins; Humans; Peptide Fragments; Perioperative Care; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombosis | 2018 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
7 trial(s) available for arginine and hirudin
Article | Year |
---|---|
Rationale and design of the PREVENT-HIT study: a randomized, open-label pilot study to compare desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis.
Topics: Anticoagulants; Arginine; Female; Heparin; Hirudins; Humans; Male; Pilot Projects; Pipecolic Acids; Prospective Studies; Recombinant Proteins; Research Design; Sulfonamides; Thrombocytopenia; Thrombosis | 2010 |
A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: PREVENT-HIT Study.
Topics: Adolescent; Adult; Aged; Anticoagulants; Arginine; Disease Progression; Female; Hemorrhage; Heparin; Hirudins; Humans; Male; Middle Aged; Pilot Projects; Pipecolic Acids; Platelet Count; Postoperative Complications; Postoperative Period; Recombinant Proteins; Sulfonamides; Thrombin; Thrombocytopenia; Thrombosis; Treatment Outcome; Young Adult | 2011 |
Evaluation of empiric versus nomogram-based direct thrombin inhibitor management in patients with suspected heparin-induced thrombocytopenia.
Topics: Adult; Aged; Antithrombins; Arginine; Empirical Research; Female; Heparin; Hirudins; Humans; Male; Middle Aged; Nomograms; Partial Thromboplastin Time; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombocytopenia | 2011 |
Evaluation of a standardized protocol using lepirudin or argatroban for heparin-induced thrombocytopenia.
Topics: Aged; Anticoagulants; Antithrombins; Arginine; Female; Heparin; Hirudins; Humans; Male; Middle Aged; Partial Thromboplastin Time; Pipecolic Acids; Platelet Aggregation Inhibitors; Recombinant Proteins; Sulfonamides; Thrombocytopenia; Treatment Outcome | 2011 |
Argatroban versus Lepirudin in critically ill patients (ALicia): a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Arginine; Critical Illness; Female; Hemorrhage; Heparin; Hirudins; Humans; Male; Middle Aged; Partial Thromboplastin Time; Pipecolic Acids; Recombinant Proteins; Renal Insufficiency; Renal Replacement Therapy; Sulfonamides; Surgical Procedures, Operative; Thrombocytopenia | 2014 |
Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry - a prospectively controlled randomized double-blind clinical trial.
Topics: Aged; Anticoagulants; Arginine; Blood Coagulation; Blood Coagulation Tests; Critical Illness; Double-Blind Method; Drug Monitoring; Female; Hirudins; Humans; Male; Middle Aged; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombelastography | 2018 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
124 other study(ies) available for arginine and hirudin
Article | Year |
---|---|
Desulfated hirugen (hirudin 54-65) induces endothelium-dependent relaxation of porcine pulmonary arteries.
Topics: 1-Methyl-3-isobutylxanthine; Amino Acid Sequence; Animals; Arginine; Atropine; Bradykinin; Calcium; Captopril; Cyclic GMP; Dinoprost; Endothelium, Vascular; Hirudins; Histamine; Indomethacin; Ketanserin; Methiothepin; Molecular Sequence Data; Muscle, Smooth, Vascular; Nitric Oxide; Nitroarginine; Peptide Fragments; Phentolamine; Pulmonary Artery; Swine; Vasodilation | 1994 |
Effects of activation peptide bond cleavage and fragment 2 interactions on the pathway of exosite I expression during activation of human prethrombin 1 to thrombin.
Topics: Arginine; Binding Sites; Enzyme Precursors; Factor Xa; Fluoresceins; Fluorescent Dyes; Hirudins; Humans; Peptide Fragments; Protein Conformation; Prothrombin; Spectrometry, Fluorescence; Thermodynamics; Threonine; Thrombin | 2003 |
The inducible nitric oxide synthase is impaired by thrombin in vascular smooth muscle cells.
Topics: Amino Acid Oxidoreductases; Animals; Aorta; Arginine; Cells, Cultured; Enzyme Induction; Hirudins; Interleukin-1; Muscle, Smooth, Vascular; Nitric Oxide Synthase; Nitroarginine; Phenylephrine; Rats; Thrombin; Vasodilation | 1992 |
Aprotinin inhibits platelet adhesion to endothelial cells.
Topics: Aprotinin; Arginine; Aspirin; Cells, Cultured; Collagen; Depression, Chemical; Endothelium, Vascular; Hirudins; Humans; Infant, Newborn; Nitric Oxide; omega-N-Methylarginine; Plastics; Platelet Adhesiveness; Thrombin; Umbilical Veins | 1992 |
The pharmacological modulation of thrombin-induced cerebral thromboembolism in the rabbit.
Topics: Animals; Anistreplase; Arginine; Blood Platelets; Diterpenes; Female; Fibrinogen; Fibrinolytic Agents; Ginkgolides; Hirudins; Injections, Intra-Arterial; Injections, Intravenous; Intracranial Embolism and Thrombosis; Lactones; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Platelet Activating Factor; Platelet Aggregation; Platelet Aggregation Inhibitors; Polydeoxyribonucleotides; Rabbits; Recombinant Proteins; Thrombin | 1992 |
"Thrombin" receptor-directed ligand accounts for activation by thrombin of platelet phospholipase C and accumulation of 3-phosphorylated phosphoinositides.
Topics: Amino Acid Sequence; Arginine; Blood Platelets; Dansyl Compounds; Enzyme Activation; Hirudins; Humans; Kinetics; Ligands; Molecular Sequence Data; Peptide Fragments; Phosphatidylinositols; Phosphorylation; Receptors, Cell Surface; Receptors, Thrombin; Thrombin; Type C Phospholipases | 1991 |
The interaction of thrombin with platelet protease nexin.
Topics: Amyloid beta-Protein Precursor; Arginine; Blood Platelets; Carrier Proteins; Dansyl Compounds; Hirudins; Humans; Iodine Radioisotopes; Platelet Activation; Protease Inhibitors; Protease Nexins; Receptors, Cell Surface; Thrombin | 1989 |
Antithrombotic effects of three thrombin inhibitors in a rat model of laser-induced thrombosis.
Topics: Animals; Antithrombins; Arginine; Disease Models, Animal; Hirudins; Humans; Injections, Intravenous; Lasers; Light Coagulation; Pipecolic Acids; Rats; Rats, Inbred Strains; Sulfonamides; Thrombosis | 1989 |
Effect of thrombin inhibitors on thrombin-induced platelet release and aggregation.
Topics: Adenosine Triphosphate; Antimycin A; Arginine; Binding Sites; Blood Platelets; Chymotrypsin; Dansyl Compounds; Deoxyglucose; Hirudins; Humans; In Vitro Techniques; Platelet Aggregation; Thrombin; Time Factors | 1988 |
Inhibited thrombins. Interactions with fibrinogen and fibrin.
Topics: Amino Acid Chloromethyl Ketones; Arginine; Binding Sites; Chromatography, Affinity; Dansyl Compounds; Dipeptides; Fibrin; Fibrinogen; Fluorescent Dyes; Hirudins; Phenylmethylsulfonyl Fluoride; Protein Binding; Pyridoxal Phosphate; Thrombin | 1987 |
[On the presence of a trypsin-plasmin inhibitor in hirudin].
Topics: Arginine; Chromatography, Gel; Esters; Fibrinolysin; Hirudins; Thrombin; Trypsin Inhibitors | 1969 |
[Identification of lysine and arginine residues as inhibitory centers of protease inhibitors by means of maleic anhydride and butane-(2.3)-dione].
Topics: Amino Acid Sequence; Animals; Arginine; Binding Sites; Butanones; Cats; Cattle; Chymotrypsin; Dogs; Fibrinolysin; Furans; Hirudins; Indicators and Reagents; Kallikreins; Lung; Lysine; Male; Pancreas; Protease Inhibitors; Seminal Vesicles; Sheep; Swine; Trypsin Inhibitors; Vegetables | 1969 |
An evaluation of the utility of benzoyl-DL-arginine-beta-naphthyl-amide for the assay of thrombin activity in blood.
Topics: Animals; Arginine; Benzamides; Cattle; Coronary Disease; Coumarins; Factor VIII; Fibrinogen; Hirudins; Humans; Hydrolysis; Naphthalenes; Protein Binding; Prothrombin; Serum Albumin; Thrombin; Thromboplastin | 1974 |
Preparation and properties of water-insoluble thrombin.
Topics: Arginine; Benzyl Compounds; Esterases; Esters; Hirudins; Kinetics; Methylcellulose; Solubility; Thrombin | 1971 |
Thrombin stimulation of guanosine 3',5'-monophosphate formation in murine neuroblastoma cells (clone N1E-115).
Topics: Animals; Arginine; Blood Platelets; Catechols; Clone Cells; Cyclic GMP; Dansyl Compounds; Hirudins; Indomethacin; Masoprocol; Mice; Neuroblastoma; Thrombin; Trypsin | 1983 |
Effect of an impermeant arginine-modifying reagent on the responses of rabbit platelets to agonists.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Aldehydes; Animals; Arginine; Binding, Competitive; Cell Membrane Permeability; Hirudins; Phentolamine; Phenylglyoxal; Platelet Aggregation; Rabbits; Receptors, Cell Surface; Receptors, Purinergic; Serotonin Antagonists; Thrombin | 1983 |
Comparative studies on thrombin inhibitors in experimental microthrombosis.
Topics: 4-Aminobenzoic Acid; Animals; Arginine; Dipeptides; Female; Fibrinogen; Hirudins; Kinetics; Lung; Male; Microcirculation; para-Aminobenzoates; Piperidines; Rats; Rats, Inbred Strains; Thrombin; Thrombosis | 1983 |
Direct inhibition of protein Ca by site directed thrombin inhibitors: implications in anticoagulant and thrombolytic therapy.
Topics: Antifibrinolytic Agents; Antithrombin III; Antithrombins; Aprotinin; Arginine; Binding Sites; Boron Compounds; Enzyme Activation; Fibrinolysis; Heparin; Hirudins; Humans; Oligopeptides; Peptide Fragments; Pipecolic Acids; Protein C; Recombinant Proteins; Sulfonamides; Thrombin | 1995 |
Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog, and hirudin.
Topics: Amino Acid Sequence; Anticoagulants; Antithrombins; Arginine; Endopeptidases; Feedback; Hirudins; Humans; Molecular Sequence Data; Oligopeptides; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides | 1995 |
Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin.
Topics: Antithrombins; Arginine; Blood Coagulation; Dipeptides; Dose-Response Relationship, Drug; Fibrin; Heparin; Hirudins; Humans; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombin | 1994 |
Alpha-thrombin and trypsin use different receptors to stimulate arachidonic acid metabolism.
Topics: Amino Acid Sequence; Animals; Arginine; Cells, Cultured; Dansyl Compounds; Epoprostenol; Hirudins; Liver; Molecular Sequence Data; Peptide Fragments; Rats; Receptor, PAR-2; Receptors, Cell Surface; Receptors, Thrombin; Thrombin; Thrombomodulin; Trypsin | 1994 |
In vitro and in vivo characterization of a neutral boron-containing thrombin inhibitor.
Topics: Animals; Antithrombins; Arginine; Blood Coagulation Tests; Boron; Bridged Bicyclo Compounds; Cells, Cultured; Dipeptides; Hirudins; Humans; Kinetics; Male; Oligopeptides; Pipecolic Acids; Piperidines; Platelet Activation; Platelet Aggregation; Rats; Rats, Wistar; Sulfonamides; Thrombin | 1993 |
Inhibition by Argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin.
Topics: Animals; Antithrombin III; Antithrombins; Arginine; Fibrin; Fibrinolytic Agents; Heparin; Hirudins; Pipecolic Acids; Platelet Activation; Platelet Aggregation Inhibitors; Rabbits; Recombinant Proteins; Sulfonamides; Thrombosis | 1996 |
Crystal structure of two new bifunctional nonsubstrate type thrombin inhibitors complexed with human alpha-thrombin.
Topics: Amino Acid Sequence; Antithrombins; Arginine; Binding Sites; Coagulants; Crystallization; Crystallography, X-Ray; Fibrinogen; Hirudins; Humans; Hydrogen Bonding; Hydrolysis; Naphthalenesulfonates; Peptide Fragments; Peptides; Pipecolic Acids; Protein Structure, Secondary; Serine Proteinase Inhibitors; Sulfonamides; Thrombin | 1996 |
Comparative anticoagulant effects of various thrombin inhibitors, as determined in the ecarin clotting time method.
Topics: Antithrombins; Arginine; Blood Coagulation Tests; Boron Compounds; Dose-Response Relationship, Drug; Endopeptidases; Enzyme Precursors; Fibrinolytic Agents; Heparin; Hirudins; Humans; Oligopeptides; Partial Thromboplastin Time; Pipecolic Acids; Prothrombin; Sulfonamides; Thrombin | 1996 |
Inhibitory mechanism of serpins. Identification of steps involving the active-site serine residue of the protease.
Topics: Amyloid beta-Protein Precursor; Antithrombin III; Arginine; Binding Sites; Binding, Competitive; Carrier Proteins; Dansyl Compounds; Fluorescence; Heparin; Hirudins; Kinetics; Protease Nexins; Receptors, Cell Surface; Recombinant Proteins; Serine; Serine Endopeptidases; Serpins; Thrombin; Titrimetry | 1997 |
Functional characterization of recombinant human meizothrombin and Meizothrombin(desF1). Thrombomodulin-dependent activation of protein C and thrombin-activatable fibrinolysis inhibitor (TAFI), platelet aggregation, antithrombin-III inhibition.
Topics: Antithrombin III; Arginine; Binding, Competitive; Blood Coagulation; Dansyl Compounds; Enzyme Activation; Enzyme Precursors; Hirudins; Humans; Platelet Aggregation; Protein C; Recombinant Proteins; Structure-Activity Relationship; Thrombin; Thrombomodulin | 1997 |
Heparin facilitates dissociation of complexes between thrombin and a reactive site mutant (L444R) of heparin cofactor II.
Topics: Arginine; Binding Sites; Dermatan Sulfate; Heparin; Heparin Cofactor II; Hirudins; Humans; Kinetics; Leucine; Mutagenesis, Site-Directed; Protein Conformation; Recombinant Proteins; Sodium Dodecyl Sulfate; Thrombin | 1997 |
Comparative intravenous antithrombotic actions of heparin and site directed thrombin inhibitors in a jugular vein clamping model.
Topics: Animals; Antithrombins; Arginine; Constriction; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fibrinolytic Agents; Heparin; Hirudins; Injections, Intravenous; Jugular Veins; Male; Models, Cardiovascular; Peptide Fragments; Pipecolic Acids; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Sulfonamides | 1996 |
Inhibition of thrombin generation in plasma by inhibitors of factor Xa.
Topics: Animals; Anticoagulants; Arginine; Arthropod Proteins; Cattle; Dipeptides; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Hirudins; Humans; Intercellular Signaling Peptides and Proteins; Kinetics; Molecular Structure; Naphthalenes; Partial Thromboplastin Time; Peptides; Pipecolic Acids; Piperidines; Propionates; Rabbits; Recombinant Proteins; Serine Proteinase Inhibitors; Sulfonamides; Sulfones; Thrombin; Thromboplastin | 1997 |
The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
Topics: Amino Acid Chloromethyl Ketones; Animals; Anticoagulants; Arginine; Azetidines; Benzylamines; Carotid Artery Thrombosis; Dose-Response Relationship, Drug; Fibrinolytic Agents; Glycine; Hemodynamics; Heparin; Hirudin Therapy; Hirudins; Kinetics; Male; Oligopeptides; Partial Thromboplastin Time; Peptide Fragments; Pipecolic Acids; Piperidines; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Sulfonamides; Thrombin; Thrombin Time | 1997 |
BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
Topics: Animals; Anticoagulants; Arginine; Arteries; Glycine; Heparin; Hirudins; Humans; Infusions, Intravenous; Oligopeptides; Peptide Fragments; Pipecolic Acids; Piperidines; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Sulfonamides; Thrombin; Thrombosis; Veins | 1998 |
Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity.
Topics: Alanine; Amino Acid Substitution; Arginine; Catalysis; Electrophoresis, Polyacrylamide Gel; Factor IX; Factor VIIIa; Heparin; Hirudins; Humans; Protein Binding; Recombinant Proteins | 1998 |
Synthesis and characterization of more potent analogues of hirudin fragment 1-47 containing non-natural amino acids.
Topics: Alanine; Amino Acid Sequence; Amino Acid Substitution; Animals; Arginine; Cattle; Circular Dichroism; Glycine; Hirudins; Humans; Molecular Sequence Data; Peptide Fragments; Phenylalanine; Serine; Spectrometry, Fluorescence; Thrombin; Tyrosine; Valine | 1998 |
Platelet agonists enhance the import of phosphatidylethanolamine into human platelets.
Topics: Adenosine Diphosphate; Apolipoproteins B; Arachidonic Acid; Arginine; Biological Transport; Blood Coagulation; Blood Platelets; Collagen; Dansyl Compounds; Hirudins; Humans; Lipoproteins, LDL; Peptide Fragments; Phosphatidylethanolamines; Phospholipids; Platelet Activation; Protein Kinase C | 1998 |
Platelet aggregation induced in vitro by rabbit plasma clot-associated thrombin, and its inhibition by thrombin inhibitors.
Topics: Animals; Antithrombin III; Arginine; Blood Coagulation; Blood Platelets; Heparin; Hirudins; Humans; Male; Microscopy, Electron, Scanning; Pipecolic Acids; Platelet Aggregation; Platelet Aggregation Inhibitors; Rabbits; Recombinant Proteins; Sulfonamides; Thrombin; Thromboplastin | 1998 |
Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban.
Topics: Amino Acid Sequence; Animals; Arginine; Arterial Occlusive Diseases; Arteriovenous Shunt, Surgical; Chlorides; Drug Evaluation, Preclinical; Ferric Compounds; Fibrinolytic Agents; Glass; Hemorrhage; Heparin; Hirudin Therapy; Hirudins; Molecular Sequence Data; Pipecolic Acids; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Recombinant Proteins; Sequence Alignment; Sequence Homology, Amino Acid; Serine Proteinase Inhibitors; Sulfonamides; Thrombin; Thrombosis; Vena Cava, Inferior; Venous Thrombosis | 1999 |
Platelet activation with unfractionated heparin at therapeutic concentrations and comparison with low-molecular-weight heparin and with a direct thrombin inhibitor.
Topics: Angina, Unstable; Anticoagulants; Antithrombins; Arginine; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; Pipecolic Acids; Platelet Activation; Platelet Aggregation Inhibitors; Sulfonamides; Thrombolytic Therapy | 1999 |
Comparative trial of local pharmacotherapy with L-arginine, r-hirudin, and molsidomine to reduce restenosis after balloon angioplasty of stenotic rabbit iliac arteries.
Topics: Administration, Topical; Angioplasty, Balloon; Animals; Antithrombins; Arginine; Constriction, Pathologic; Hirudin Therapy; Hirudins; Iliac Artery; Male; Molsidomine; Nitric Oxide Donors; Rabbits; Recurrence; Vasodilator Agents | 2001 |
Direct thrombin inhibitors: are they the future of anticoagulation?
Topics: Anticoagulants; Arginine; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombin | 2001 |
Comment: treatment of heparin-induced thrombocytopenia.
Topics: Anticoagulants; Arginine; Heparin; Hirudins; Humans; International Normalized Ratio; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombin; Thrombocytopenia; Warfarin | 2002 |
Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Anticoagulants; Arginine; Autoimmune Diseases; Catheterization, Central Venous; Contraindications; Drug Administration Schedule; Drug Therapy, Combination; Female; Gangrene; Heparin; Hirudin Therapy; Hirudins; Humans; International Normalized Ratio; Leg; Male; Middle Aged; Necrosis; Pipecolic Acids; Protein C Deficiency; Recombinant Proteins; Sulfonamides; Surgical Wound Infection; Thrombin; Thrombocytopenia; Thrombophlebitis; Warfarin | 2002 |
Monitoring of anticoagulant effects of direct thrombin inhibitors.
Topics: Anticoagulants; Arginine; Azetidines; Benzylamines; Blood Coagulation Tests; Drug Monitoring; Glycine; Heparin; Hirudins; Humans; Pipecolic Acids; Recombinant Proteins; Sensitivity and Specificity; Sulfonamides; Thrombin | 2002 |
Influence of lepirudin, argatroban, and melagatran on prothrombin time and additional effect of oral anticoagulation.
Topics: Administration, Oral; Anticoagulants; Arginine; Azetidines; Benzylamines; Drug Synergism; Glycine; Hirudins; Humans; Phenprocoumon; Pipecolic Acids; Prothrombin Time; Recombinant Proteins; Sulfonamides | 2002 |
Preventing complications in heparin-induced thrombocytopenia. Alternative anticoagulants are improving patient outcomes.
Topics: Anticoagulants; Arginine; Chondroitin Sulfates; Dermatan Sulfate; Drug Combinations; Heparin; Heparinoids; Heparitin Sulfate; Hirudin Therapy; Hirudins; Humans; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombocytopenia | 2002 |
Direct antithrombin agents ameliorate disseminated intravascular coagulation in suspected heparin-induced thrombocytopenia thrombosis syndrome.
Topics: Adult; Aged; Arginine; Disseminated Intravascular Coagulation; Female; Fibrinolytic Agents; Heparin; Hirudins; Humans; Male; Middle Aged; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombocytopenia | 2002 |
Anticoagulation in acute cardiac care in patients with chronic kidney disease.
Topics: Anticoagulants; Antithrombins; Arginine; Chronic Disease; Coronary Disease; Heparin; Heparin, Low-Molecular-Weight; Hirudin Therapy; Hirudins; Humans; Kidney Diseases; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; United States | 2003 |
Predicting the pharmacology of thrombin inhibitors.
Topics: Anticoagulants; Arginine; Azetidines; Benzylamines; Blood Coagulation; Computer Simulation; Dose-Response Relationship, Drug; Glycine; Hirudins; Humans; Kinetics; Models, Cardiovascular; Oligopeptides; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombin | 2003 |
[Free arginine and histidine content in plasma and erythrocytes in acute cerebrovascular syndrome].
Topics: Arginine; Brain; Cardiovascular System; Erythrocytes; Hirudins; Histidine; Humans; Plasma | 1953 |
Argatroban for off-pump coronary artery bypass surgery.
Topics: Anticoagulants; Arginine; Blood Coagulation Tests; Coronary Artery Bypass; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides | 2003 |
Clinician update: direct thrombin inhibitors in acute coronary syndromes.
Topics: Acute Disease; Arginine; Coronary Disease; Fibrinolytic Agents; Hirudin Therapy; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombin | 2003 |
Treatment options for heparin-induced thrombocytopenia.
Topics: Antithrombins; Arginine; Heparin; Hirudins; Humans; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombocytopenia; Thrombosis; United States | 2003 |
Proexosite-1-dependent recognition and activation of prothrombin by taipan venom.
Topics: Antithrombins; Arginine; Binding Sites; Chromatography; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Factor Va; Hirudins; Humans; Kinetics; Lysine; Models, Chemical; Mutation; Peptide Hydrolases; Peptides; Prothrombin; Recombinant Proteins | 2004 |
Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values.
Topics: Antithrombins; Arginine; Dose-Response Relationship, Drug; Hirudins; Humans; In Vitro Techniques; International Normalized Ratio; Peptide Fragments; Pipecolic Acids; Prothrombin Time; Recombinant Proteins; Sulfonamides | 2004 |
Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing.
Topics: Arginine; Blood Coagulation; Dose-Response Relationship, Drug; Endopeptidases; Fibrinolytic Agents; Hirudins; Humans; In Vitro Techniques; Partial Thromboplastin Time; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombin | 2004 |
Effects of pentasaccharide (fondaparinux) and direct thrombin inhibitors on coagulation testing.
Topics: Antithrombins; Arginine; Blood Coagulation Tests; Fondaparinux; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Polysaccharides; Recombinant Proteins; Sulfonamides | 2004 |
Argatroban treatment for patients with intolerance to heparin and hirudin.
Topics: Adolescent; Adult; Aged; Arginine; Contraindications; Drug Hypersensitivity; Female; Heparin; Hirudins; Humans; Middle Aged; Pipecolic Acids; Sulfonamides | 2005 |
Treatment of patients with a history of heparin-induced thrombocytopenia and anti-lepirudin antibodies with argatroban.
Topics: Aged; Antibodies; Anticoagulants; Arginine; Enzyme-Linked Immunosorbent Assay; Female; Heparin; Hirudin Therapy; Hirudins; Humans; Immunoglobulin G; Male; Middle Aged; Pipecolic Acids; Platelet Aggregation Inhibitors; Recombinant Proteins; Sulfonamides; Thrombocytopenia | 2005 |
Collaborative study on monitoring methods to determine direct thrombin inhibitors lepirudin and argatroban.
Topics: Arginine; Blood Coagulation Tests; Cooperative Behavior; Drug Monitoring; Enzyme-Linked Immunosorbent Assay; Fibrinolytic Agents; Hirudins; Humans; Methods; Pipecolic Acids; Recombinant Proteins; Reproducibility of Results; Sulfonamides; Thrombin | 2005 |
The paradox of heparin-induced thrombocytopenia: the initial management.
Topics: Anticoagulants; Arginine; Heparin; Hirudins; Humans; Pipecolic Acids; Platelet Aggregation Inhibitors; Recombinant Proteins; Sulfonamides; Thrombocytopenia | 2005 |
Presence of direct thrombin inhibitors can affect the results and interpretation of lupus anticoagulant testing.
Topics: Anticoagulants; Arginine; Blood Coagulation; Blood Coagulation Tests; Dose-Response Relationship, Drug; Heparin; Hirudins; Humans; In Vitro Techniques; Lupus Coagulation Inhibitor; Partial Thromboplastin Time; Peptide Fragments; Pipecolic Acids; Prothrombin Time; Recombinant Proteins; Reference Values; Sulfonamides; Viper Venoms | 2005 |
Direct thrombin inhibitors are not equally effective in vivo against arterial thrombosis: in vivo evaluation of DuP714 and argatroban in a porcine angioplasty model and comparison to r-hirudin.
Topics: Angioplasty, Balloon; Animals; Anticoagulants; Arginine; Boron Compounds; Drug Evaluation, Preclinical; Hirudins; Oligopeptides; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Swine; Thrombin; Thrombosis | 2005 |
Argatroban and lepirudin requirements in a 6-year-old patient with heparin-induced thrombocytopenia.
Topics: Anticoagulants; Arginine; Child; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Heparin; Hirudins; Humans; Partial Thromboplastin Time; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombocytopenia | 2005 |
Argatroban and lepirudin: clinical trials to clinical practice.
Topics: Anticoagulants; Arginine; Clinical Trials as Topic; Hirudins; Humans; Pipecolic Acids; Recombinant Proteins; Sulfonamides | 2005 |
A comparison of lepirudin and argatroban outcomes.
Topics: Aged; Anticoagulants; Arginine; Female; Hemorrhage; Hirudins; Humans; Male; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombin; Treatment Outcome | 2005 |
Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia.
Topics: Anticoagulants; Arginine; Cohort Studies; Female; Heparin; Hirudins; Humans; Male; Middle Aged; Partial Thromboplastin Time; Pipecolic Acids; Platelet Activation; Platelet Aggregation; Recombinant Proteins; Retrospective Studies; Sulfonamides; Thrombocytopenia | 2005 |
Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
Topics: Animals; Anticoagulants; Arginine; Azetidines; Benzylamines; Blood Coagulation; Cattle; Dose-Response Relationship, Drug; Factor Xa; Factor Xa Inhibitors; Glycine; Hirudins; Humans; In Vitro Techniques; Partial Thromboplastin Time; Peptide Fragments; Pipecolic Acids; Prothrombin Time; Recombinant Proteins; Species Specificity; Sulfonamides; Thrombin; Thrombin Time; Thromboplastin | 2005 |
Heparin-induced thrombocytopenia and cardiovascular patients: recognition and treatment.
Topics: Anticoagulants; Arginine; Heparin; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Platelet Factor 4; Recombinant Proteins; Sulfonamides; Thrombocytopenia | 2006 |
Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arginine; Female; Heparin; Hirudins; Humans; Male; Middle Aged; Partial Thromboplastin Time; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Retrospective Studies; Sulfonamides; Thrombin; Thrombocytopenia; Time Factors; Treatment Outcome | 2006 |
Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro.
Topics: Anticoagulants; Antithrombins; Arginine; Cardiopulmonary Bypass; Child; Dose-Response Relationship, Drug; Fatal Outcome; Female; Fibrinolytic Agents; Heart Transplantation; Heparin; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Platelet Aggregation Inhibitors; Recombinant Proteins; Sulfonamides; Thrombelastography; Thrombocytopenia; Treatment Failure; Whole Blood Coagulation Time | 2006 |
[Two surgical case reports showing atypical heparin-induced thrombocytopenia].
Topics: Adult; Anticoagulants; Arginine; Chondroitin Sulfates; Dermatan Sulfate; Drug Eruptions; Female; Heparin; Heparin, Low-Molecular-Weight; Heparitin Sulfate; Hirudins; Humans; Male; Pipecolic Acids; Platelet Count; Platelet Factor 4; Postoperative Complications; Recombinant Proteins; Sulfonamides; Thrombocytopenia; Thrombosis; Time Factors | 2007 |
Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation.
Topics: Anticoagulants; Antithrombins; Arginine; Blood Coagulation; Drug Evaluation, Preclinical; Elasticity; Enoxaparin; Fondaparinux; Heparin; Hirudins; Humans; Kinetics; Peptide Fragments; Pipecolic Acids; Polysaccharides; Recombinant Proteins; Stress, Mechanical; Sulfonamides; Thrombelastography; Thrombin | 2007 |
Impact of smart infusion technology on administration of anticoagulants (unfractionated Heparin, Argatroban, Lepirudin, and Bivalirudin).
Topics: Anticoagulants; Arginine; Boston; Drug Overdose; Drug Therapy, Computer-Assisted; Heparin; Hirudins; Humans; Infusion Pumps; Infusions, Intravenous; Medication Errors; Medication Systems, Hospital; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Research Design; Sulfonamides | 2007 |
Seizures, headache and thrombocytopenia: diagnosis and treatment do not always come in a standard sequence.
Topics: Arginine; Female; Headache; Heparin, Low-Molecular-Weight; Hirudins; Humans; Middle Aged; Pipecolic Acids; Recombinant Proteins; Seizures; Sulfonamides; Thrombocytopenia | 2007 |
Inhibition of thrombin generation in recalcified plasma.
Topics: Anticoagulants; Aprotinin; Arginine; Blood Coagulation Tests; Chondroitin Sulfates; Dermatan Sulfate; Fondaparinux; Heparin; Heparitin Sulfate; Hirudins; Humans; Pipecolic Acids; Plant Proteins; Plasma; Polysaccharides; Sulfonamides; Thrombin | 2007 |
Fondaparinux versus direct thrombin inhibitor therapy for the management of heparin-induced thrombocytopenia (HIT)--bridging the River Coumarin.
Topics: Acute Disease; Anticoagulants; Arginine; Blood Coagulation; Factor Xa Inhibitors; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; International Normalized Ratio; Pipecolic Acids; Platelet Count; Polysaccharides; Recombinant Proteins; Research Design; Sulfonamides; Thrombin; Thrombocytopenia; Treatment Outcome; Venous Thrombosis; Warfarin | 2008 |
Standardizing the management of heparin-induced thrombocytopenia.
Topics: Anticoagulants; Arginine; Clinical Protocols; Evidence-Based Medicine; Fondaparinux; Heparin; Hirudins; Humans; Pipecolic Acids; Platelet Count; Platelet Function Tests; Polysaccharides; Recombinant Proteins; Retrospective Studies; Sulfonamides; Thrombocytopenia | 2008 |
The interaction of fragment 1 of prothrombin with the membrane surface is a prerequisite for optimum expression of factor Va cofactor activity within prothrombinase.
Topics: Arginine; Binding Sites; Cell Membrane; Cells, Cultured; Endothelial Cells; Enzyme Inhibitors; Enzyme Precursors; Factor V; Factor Va; Factor Xa; Hirudins; Humans; Kinetics; Models, Molecular; Peptide Fragments; Protein Binding; Protein Conformation; Protein Precursors; Prothrombin; Thrombin; Thromboplastin | 2008 |
[Heparin induced thrombocytopenia and anticoagulation in renal replacemant therapy].
Topics: Acute Kidney Injury; Anticoagulants; Arginine; Blood Coagulation Tests; Chondroitin Sulfates; Citrates; Critical Care; Dermatan Sulfate; Diagnostic Errors; Dose-Response Relationship, Drug; Epoprostenol; Fondaparinux; Hemofiltration; Heparin; Heparin, Low-Molecular-Weight; Heparitin Sulfate; Hirudins; Humans; Iloprost; Pipecolic Acids; Polysaccharides; Recombinant Proteins; Sodium Citrate; Sulfonamides; Thrombocytopenia; Thrombosis | 2008 |
Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Topics: Anticoagulants; Arginine; Biological Availability; Chondroitin Sulfates; Dermatan Sulfate; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Heparitin Sulfate; Hirudins; Humans; Infusions, Parenteral; Injections, Subcutaneous; Peptide Fragments; Pipecolic Acids; Polysaccharides; Recombinant Proteins; Sulfonamides; Thrombocytopenia | 2008 |
Management of anticoagulation in patients with subacute heparin-induced thrombocytopenia scheduled for heart transplantation.
Topics: Adult; Anticoagulants; Arginine; Autoantibodies; Heart Failure; Heart Transplantation; Heparin; Hirudins; Humans; Male; Middle Aged; Pipecolic Acids; Platelet Factor 4; Recombinant Proteins; Sulfonamides; Thrombocytopenia | 2008 |
A comparison of direct thrombin inhibitors in the treatment of Heparin-Induced Thrombocytopenia: a single institution experience.
Topics: Aged; Anticoagulants; Arginine; Female; Heparin; Hirudins; Humans; Male; Middle Aged; Pipecolic Acids; Recombinant Proteins; Retrospective Studies; Sulfonamides; Thrombocytopenia | 2009 |
The effect of ex vivo anticoagulants on whole blood platelet aggregation.
Topics: Adenosine Diphosphate; Anticoagulants; Arachidonic Acid; Arginine; Azetidines; Benzylamines; Blood Platelets; Citric Acid; Collagen; Female; Heparin; Hirudins; Humans; Male; Peptide Fragments; Pipecolic Acids; Platelet Aggregation; Platelet Function Tests; Recombinant Proteins; Ristocetin; Sulfonamides; Time Factors | 2009 |
[Heparin-induced thrombocytopenia].
Topics: Anticoagulants; Arginine; Chondroitin Sulfates; Dermatan Sulfate; Fibrinolytic Agents; Heparin; Heparitin Sulfate; Hirudins; Humans; Pipecolic Acids; Recombinant Proteins; Risk Factors; Sulfonamides; Thrombocytopenia | 2009 |
Argatroban and bivalirudin compared to unfractionated heparin in preventing thrombus formation on mechanical heart valves. Results of an in-vitro study.
Topics: Anticoagulants; Arginine; Diagnostic Techniques, Cardiovascular; Drug Therapy, Combination; Feasibility Studies; Heart Diseases; Heart-Assist Devices; Heparin; Hirudins; Humans; In Vitro Techniques; Infusion Pumps; Male; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombin; Thrombocytopenia; Thrombosis | 2009 |
The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis.
Topics: Antithrombins; Arginine; Chondroitin Sulfates; Chromatography, Gel; Dermatan Sulfate; Factor VIII; Factor Xa Inhibitors; Fibrin; Fibrinolysis; Heparinoids; Heparitin Sulfate; Hirudins; Humans; In Vitro Techniques; Microscopy, Confocal; Peptide Fragments; Pipecolic Acids; Plasma; Porosity; Protein Multimerization; Recombinant Proteins; Sulfonamides; Thrombosis; Tissue Plasminogen Activator | 2010 |
Monitoring of the anticoagulants argatroban and lepirudin: a comparison of laboratory methods.
Topics: Antithrombins; Arginine; Calibration; Female; Hirudins; Humans; Male; Partial Thromboplastin Time; Pipecolic Acids; Prothrombin Time; Recombinant Proteins; Sulfonamides; Thrombin Time | 2011 |
[Determination of biological activity of extract from hirudo by N-benzoyl-L-arginine ethyl ester].
Topics: Animals; Arginine; Biological Factors; Enzyme Assays; Enzyme Inhibitors; Hirudins; Hirudo medicinalis; Thrombin | 2010 |
Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia.
Topics: Antithrombins; Arginine; Female; Heparin; Hirudins; Humans; Male; Middle Aged; Partial Thromboplastin Time; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Retrospective Studies; Sulfonamides; Thrombocytopenia; Time Factors | 2010 |
Thrombolytic therapy and thrombectomy in phlegmasia cerulea dolens.
Topics: Anticoagulants; Antithrombins; Arginine; Fibrinolytic Agents; Heparin; Hirudins; Humans; Pipecolic Acids; Platelet Aggregation Inhibitors; Recombinant Proteins; Sulfonamides; Thrombectomy; Thrombocytopenia; Time Factors; Venous Thrombosis | 2010 |
Practical viewpoints on the diagnosis and management of heparin-induced thrombocytopenia.
Topics: Aged; Anticoagulants; Arginine; Cardiac Catheterization; Cardiac Surgical Procedures; Chondroitin Sulfates; Dermatan Sulfate; Female; Heparin; Heparin, Low-Molecular-Weight; Heparitin Sulfate; Hirudins; Humans; Male; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombocytopenia; Vascular Surgical Procedures; Vitamin K; Young Adult | 2011 |
Loading solution prevents activation damage of human platelets before lyophilization.
Topics: Adenosine; Algorithms; Alprostadil; Arginine; Biomarkers; Blood Platelets; Blood Preservation; Cell Size; Cilostazol; Excipients; Freeze Drying; Hirudins; Humans; P-Selectin; Peptide Fragments; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Membrane Glycoproteins; Recombinant Proteins; Tetrazoles | 2011 |
Development and implementation of a comprehensive heparin-induced thrombocytopenia recognition and management protocol.
Topics: Academic Medical Centers; Anticoagulants; Antithrombins; Arginine; Heparin; Hirudins; Humans; Joint Commission on Accreditation of Healthcare Organizations; Patient Education as Topic; Pharmacists; Pipecolic Acids; Practice Guidelines as Topic; Quality Assurance, Health Care; Recombinant Proteins; Sulfonamides; Thrombin; Thrombocytopenia; United States | 2012 |
In vivo fluorescence imaging of atherosclerotic plaques with activatable cell-penetrating peptides targeting thrombin activity.
Topics: Amino Acid Sequence; Animals; Antithrombins; Aorta; Arginine; Cell-Penetrating Peptides; Fluorescent Dyes; Hirudins; Histocytochemistry; Humans; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Microscopy, Fluorescence; Pipecolic Acids; Plaque, Atherosclerotic; Receptor, PAR-1; Recombinant Proteins; Sulfonamides; Thrombin | 2012 |
The therapeutic management of bleeding and thrombotic disorders complicating CNS malignancies.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Bevacizumab; Central Nervous System Neoplasms; Fondaparinux; Glioblastoma; Glioma; Hemorrhage; Heparin, Low-Molecular-Weight; Hirudins; Humans; Pipecolic Acids; Polysaccharides; Postoperative Complications; Pulmonary Embolism; Recombinant Proteins; Sulfonamides; Thrombocytopenia; Vena Cava Filters; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2012 |
Alternative anticoagulation during cardiovascular procedures in pediatric patients with heparin-induced thrombocytopenia.
Topics: Antithrombins; Arginine; Cardiopulmonary Bypass; Heparin; Hirudins; Humans; Infant; Infant, Newborn; Male; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombocytopenia | 2012 |
Direct thrombin inhibitors for management of heparin-induced thrombocytopenia in patients receiving renal replacement therapy: comparison of clinical outcomes.
Topics: Adult; Aged; Anticoagulants; Antithrombins; Arginine; Female; Heparin; Hirudins; Humans; International Normalized Ratio; Male; Middle Aged; Peptide Fragments; Pipecolic Acids; Platelet Count; Recombinant Proteins; Renal Replacement Therapy; Retrospective Studies; Serum Albumin; Sulfonamides; Thrombocytopenia | 2012 |
Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: which assay is helpful?
Topics: Antithrombins; Arginine; Blood Coagulation; Chromogenic Compounds; Diagnostic Tests, Routine; Endopeptidases; Fibrinolytic Agents; Hirudins; Humans; Partial Thromboplastin Time; Peptide Fragments; Pipecolic Acids; Prothrombin Time; Recombinant Proteins; Sulfonamides; Thrombin; Thrombin Time | 2012 |
Safety and effectiveness outcomes of an inpatient collaborative drug therapy management service for direct thrombin inhibitors.
Topics: Adult; Aged; Antithrombins; Arginine; Cohort Studies; Cooperative Behavior; Drug Monitoring; Female; Hemorrhage; Heparin; Hirudins; Humans; Inpatients; Male; Medication Errors; Middle Aged; Outcome Assessment, Health Care; Partial Thromboplastin Time; Peptide Fragments; Pharmacists; Pharmacy Service, Hospital; Pipecolic Acids; Recombinant Proteins; Retrospective Studies; Sulfonamides; Thrombocytopenia; Time Factors | 2012 |
Monitoring the direct thrombin inhibitors.
Topics: Antithrombins; Arginine; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides | 2013 |
Direct thrombin inhibitors and factor xa inhibitors can influence the diluted prothrombin time used as the initial screen for lupus anticoagulant.
Topics: Anticoagulants; Antithrombins; Arginine; Chondroitin Sulfates; Dermatan Sulfate; Enoxaparin; Factor Xa Inhibitors; False Positive Reactions; Fondaparinux; Heparitin Sulfate; Hirudins; Humans; Lupus Coagulation Inhibitor; Mass Screening; Pipecolic Acids; Polysaccharides; Prothrombin Time; Recombinant Proteins; Sulfonamides; Thrombin | 2013 |
Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples.
Topics: Antithrombins; Arginine; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Heparin; Hirudins; Humans; Partial Thromboplastin Time; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombin; Thrombin Time; Thromboplastin | 2014 |
Bivalirudin for the treatment of patients with confirmed or suspected heparin-induced thrombocytopenia.
Topics: Adult; Aged; Anticoagulants; Antithrombins; Arginine; Female; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; Male; Middle Aged; Odds Ratio; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Registries; Retrospective Studies; Sulfonamides; Thrombocytopenia; Treatment Outcome | 2014 |
Trends in parenteral direct thrombin inhibitor use in pediatric patients: analysis of a large administrative database.
Topics: Adolescent; Age Factors; Antithrombins; Arginine; Child; Child, Preschool; Databases, Factual; Female; Health Information Systems; Hemorrhage; Hirudins; Humans; Incidence; Infant; Infant, Newborn; Infusions, Parenteral; Male; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Retrospective Studies; Sulfonamides; Thrombocytopenia; Young Adult | 2014 |
Activated protein C resistance testing for factor V Leiden.
Topics: Activated Protein C Resistance; Adult; Antithrombins; Arginine; Benzimidazoles; beta-Alanine; Biological Assay; Blood Coagulation Tests; Child; Dabigatran; Factor V; Factor Xa; False Positive Reactions; Female; Hirudins; Humans; Lupus Coagulation Inhibitor; Morpholines; Peptide Fragments; Pipecolic Acids; Pregnancy; Protein C; Recombinant Proteins; Rivaroxaban; Sulfonamides; Thiophenes; Warfarin | 2014 |
Efficacy and safety of argatroban and bivalirudine in patients with suspected heparin-induced thrombocytopenia.
Topics: Aged; Anticoagulants; Arginine; Female; Hemorrhage; Heparin; Hirudins; Humans; Male; Middle Aged; Partial Thromboplastin Time; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Retrospective Studies; Sulfonamides; Thrombocytopenia | 2015 |
Evaluation of a multi-target direct thrombin inhibitor dosing and titration guideline for patients with suspected heparin-induced thrombocytopenia.
Topics: Aged; Aged, 80 and over; Antithrombins; Arginine; Drug Administration Schedule; Drug Dosage Calculations; Drug Monitoring; Female; Heparin; Hirudins; Humans; Male; Middle Aged; Peptide Fragments; Pipecolic Acids; Practice Guidelines as Topic; Prospective Studies; Recombinant Proteins; Sulfonamides; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2015 |
Comparison of bivalirudin to lepirudin and argatroban in patients with heparin-induced thrombocytopenia.
Topics: Aged; Anticoagulants; Antithrombins; Arginine; Dose-Response Relationship, Drug; Female; Hemorrhage; Heparin; Hirudins; Humans; International Normalized Ratio; Male; Middle Aged; Partial Thromboplastin Time; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Retrospective Studies; Sulfonamides; Thrombocytopenia | 2015 |
Challenging Argatroban Management of a Child on Extracorporeal Support and Subsequent Heart Transplant.
Topics: Antithrombins; Arginine; Cardiopulmonary Bypass; Child; Exchange Transfusion, Whole Blood; Extracorporeal Membrane Oxygenation; Heart Transplantation; Heparin; Hirudins; Humans; Male; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombocytopenia | 2016 |
Effect of Thrombin Inhibitors on Positive Feedback in the Coagulation Cascade.
Topics: Antithrombins; Arginine; Blood Coagulation Tests; Feedback, Physiological; Hirudins; Humans; Kinetics; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombin | 2016 |
Overtreatment of Heparin-Induced Thrombocytopenia in the Surgical ICU.
Topics: Academic Medical Centers; Aged; Antibodies; Anticoagulants; Antithrombins; Arginine; Enzyme-Linked Immunosorbent Assay; Female; Fondaparinux; Heparin; Hirudins; Humans; Intensive Care Units; Male; Medical Overuse; Middle Aged; Pipecolic Acids; Platelet Factor 4; Polysaccharides; Prospective Studies; Recombinant Proteins; Serotonin; Sulfonamides; Thrombocytopenia | 2017 |
Rapid and durable response to intravenous immunoglobulin in delayed heparin-induced thrombocytopenia: a case report.
Topics: Arginine; Cardiac Surgical Procedures; Heparin; Hirudins; Humans; Immunoglobulins, Intravenous; Male; Middle Aged; Peptide Fragments; Pipecolic Acids; Postoperative Complications; Recombinant Proteins; Sulfonamides; Thrombocytopenia; Thrombosis | 2017 |
Monitoring of Argatroban and Lepirudin: What is the Input of Laboratory Values in "Real Life"?
Topics: Antithrombins; Arginine; Blood Coagulation Tests; Drug Monitoring; Heparin; Hirudins; Humans; Partial Thromboplastin Time; Pipecolic Acids; Prothrombin Time; Recombinant Proteins; Sulfonamides; Thrombin Time; Thrombocytopenia | 2018 |
Anticoagulation in children: Making the most of little patients and little evidence.
Topics: Anticoagulants; Arginine; Blood Coagulation; Child; Drug Monitoring; Fondaparinux; Heparin; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Polysaccharides; Recombinant Proteins; Sulfonamides; Thrombosis; Venous Thromboembolism; Warfarin | 2017 |
Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia.
Topics: Anticoagulants; Arginine; Chondroitin Sulfates; Dermatan Sulfate; Factor Xa Inhibitors; Female; Fondaparinux; Hemorrhage; Heparin; Heparitin Sulfate; Hirudins; Hospital Mortality; Hospitalization; Humans; Male; Necrosis; Off-Label Use; Partial Thromboplastin Time; Patient Safety; Pipecolic Acids; Polysaccharides; Recombinant Proteins; Registries; Retrospective Studies; Sulfonamides; Thrombocytopenia; Thromboembolism; Treatment Outcome | 2017 |
Heparin-Induced Thrombocytopenia during Obstetric Hospital Admissions.
Topics: Adolescent; Adult; Arginine; Databases, Factual; Delivery, Obstetric; Female; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Hospitalization; Humans; Middle Aged; Peptide Fragments; Pipecolic Acids; Postpartum Period; Pregnancy; Recombinant Proteins; Risk Assessment; Sulfonamides; Thrombocytopenia; United States; Young Adult | 2018 |
Self-assembled, bivalent aptamers on graphene oxide as an efficient anticoagulant.
Topics: Adsorption; Animals; Anticoagulants; Aptamers, Nucleotide; Arginine; Binding, Competitive; Blood Coagulation; DNA, Single-Stranded; Graphite; Heparin; Hirudins; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Male; Oxides; Pipecolic Acids; Protein Binding; Rats; Rats, Sprague-Dawley; Sulfonamides; Thrombin | 2018 |
American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.
Topics: Administration, Oral; Anticoagulants; Arginine; Cardiovascular Surgical Procedures; Chondroitin Sulfates; Dermatan Sulfate; Evidence-Based Medicine; Fondaparinux; Heparin; Heparitin Sulfate; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Platelet Count; Recombinant Proteins; Renal Replacement Therapy; Sulfonamides; Thrombocytopenia; Venous Thromboembolism | 2018 |
Evaluation of intravenous direct thrombin inhibitor monitoring tests: Correlation with plasma concentrations and clinical outcomes in hospitalized patients.
Topics: Adult; Aged; Antithrombins; Arginine; Female; Hirudins; Hospitalization; Humans; Infusions, Intravenous; Male; Middle Aged; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombin; Thrombin Time; Treatment Outcome | 2020 |
Argatroban Versus Bivalirudin in the Treatment of Suspected or Confirmed Heparin-Induced Thrombocytopenia.
Topics: Anticoagulants; Arginine; Heparin; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Retrospective Studies; Sulfonamides; Thrombocytopenia; Treatment Outcome | 2021 |
Survey of Anticoagulation Practices with the Impella Percutaneous Ventricular Assist Device at High-Volume Centers.
Topics: Anticoagulants; Arginine; Heart-Assist Devices; Heparin; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Practice Patterns, Physicians'; Recombinant Proteins; Sulfonamides; Surveys and Questionnaires; United States | 2019 |
Bivalirudin resistance in a patient on veno-venous extracorporeal membrane oxygenation with a therapeutic response to argatroban.
Topics: Anticoagulants; Arginine; Combined Modality Therapy; Drug Resistance; Extracorporeal Membrane Oxygenation; Hirudins; Humans; Male; Middle Aged; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Respiratory Insufficiency; Sulfonamides | 2020 |
Utilization and Outcomes of Children Treated with Direct Thrombin Inhibitors on Paracorporeal Ventricular Assist Device Support.
Topics: Adolescent; Antithrombins; Arginine; Child; Child, Preschool; Female; Heart-Assist Devices; Hemorrhage; Hirudins; Humans; Infant; Male; North America; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Retrospective Studies; Stroke; Sulfonamides; Thrombosis; Treatment Outcome | 2020 |
A journey through anticoagulant therapies in the treatment of left ventricular thrombus in post-COVID-19 heparin-induced thrombocytopenia: a case report.
Topics: Acenocoumarol; Anticoagulants; Arginine; COVID-19; COVID-19 Drug Treatment; Heparin; Hirudins; Humans; Male; Middle Aged; Peptide Fragments; Percutaneous Coronary Intervention; Pipecolic Acids; Recombinant Proteins; SARS-CoV-2; Sulfonamides; Thrombocytopenia; Thrombosis | 2022 |